Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract While PDZ-LIM domain-containing protein (PDLIM2) suppresses lung cancer, its clinical significance and therapeutic potential remain to be fully explored. Next-generation sequencing and immunohistochemistry of programmed death ligand 1 (PD-L1) were performed on lung adenocarcinoma (LUAD) tissues from 15,765 patients. PDLIM2 gene therapy was tested in syngeneic LUAD mouse models using intravenous nano-complexed plasmid DNA, alone or with chemoimmunotherapy.
On Nov. 26, the FDA announced the accelerated approval of larotrectinib as the first small molecule inhibitor for use in a “cancer-agnostic” manner, in pediatric and adult human cancers that harbor neurotrophic receptor tyrosine kinase gene fusions. This marks an important milestone in the history of targeted drug development. This landmark approval has been touted as ushering in a new paradigm in genomics-guided molecular therapeutics.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
